Trial Profile
A 3-Part, Open-label Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Lemborexant (Primary) ; Ethinylestradiol/norethisterone; Famotidine; Fluconazole
- Indications Circadian rhythm sleep disorders; Insomnia; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 05 Sep 2018 Status changed from recruiting to completed.
- 07 Mar 2018 New trial record